Abbott Laboratories has secured the FDA's blessing to launch its latest diabetes diagnostic, a test that can help diagnose and monitor diabetics as well as flag patients at risk for developing the disease.
A small molecular pump devised by researchers from the U.S., Russia and Puerto Rico could offer a new insulin delivery method for people with diabetes, using enzymes to convert chemical energy into a propulsion system for drugs.
Influenza can overwhelm the immune system of people with diabetes and lead to fluctuations in blood sugar levels. Now a study has calculated that reducing the likelihood of these complications by vaccinating against flu is associated with a 28% drop in the risk of death.
AstraZeneca won U.S. approval of its Bydureon pen for once-weekly treatment of Type 2 diabetes. The pen will be the first of its kind to hit the market. The prefilled, single-use pen injector delivers microspheres that house exenatide, which is slowly released for better glycemic control.
Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza. Lilly unveiled top-line results from a head-to-head trial between its once-weekly Type 2 diabetes remedy and the once-daily Victoza (liraglutide). And dulaglutide stood its own.
On Tuesday morning, Medtronic reported that its third quarter net earnings sank to $762 million, taking a 23% hit due in large part to setbacks in its renal denervation program and tax changes affecting the med tech industry.
One in three people in the U.S. either already have or are at high risk of developing diabetes, and analyzing genetic data for answers about how best to treat these patients is a daunting task. Now a collection of Big Pharma companies are teaming up to share the burden.
Israel's Oramed touted results from a successful Phase IIa trial of its insulin pill, saying the oral Type 2 diabetes treatment is safe and well-tolerated. But since then, some analysts and media outlets have criticized the company for being less than forthcoming about the data.
Children as young as 2 years old can now use the latest in diabetes technology, even as the company that developed it is in a race to make it yesterday's news. The FDA announced Monday it has approved a pediatric version of DexCom's G4 Platinum. The San Diego med tech now has the first continuous glucose monitor (CGM) approved in the U.S. for toddlers.
When Johnson & Johnson's new diabetes drug Invokana (canagliflozin) won FDA approval last April, it was the first drug in a brand-new class of Type II treatments. The general feeling was that doctors would need some quick education on the SGLT2 class if Invokana was to make any headway against top-selling and well-known rivals such as Sanofi's Lantus, Merck's Januvia and Novo Nordisk's Victoza.